Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 3Multiple Myeloma 2Desmoid Tumors 2Paraproteinemias 1Neoplasms, Plasma Cell 1Hematologic Diseases 1Corneal Diseases 1Breast Neoplasms 1Blood Protein Disorders 1

Interventions

fludarabine 12Cyclophosphamide 11Busulfan 8Mycophenolic Acid 6Dexamethasone 6fludarabine phosphate 5Whole-Body Irradiation 5Tacrolimus 5Melphalan 5Lenalidomide 5Granulocyte Colony-Stimulating Factor 4isatuximab 3Thiotepa 3Sirolimus 3Rituximab 3Methotrexate 3Cyclosporine 3Blood Specimen Collection 3Alemtuzumab 3pomalidomide 2pembrolizumab 2daratumumab 2Vorinostat 2Stem Cell Transplantation 2Platelet Transfusion 2Ondansetron 2Interviews as Topic 2Filgrastim 2Exercise 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Diseases × nirogacestat × Clear all
NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡